Cyclooxygenase‐2 Inhibitors can be effective in colorectal cancer prophylaxis or therapy
- سال انتشار: 1397
- محل انتشار: کنگره بین المللی جراحی سرطان شیراز
- کد COI اختصاصی: SISOC01_032
- زبان مقاله: انگلیسی
- تعداد مشاهده: 536
نویسندگان
School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
Department of Genetics, Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
Student Research Committee of Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
چکیده
Background and aim: Colorectal cancer (CRC) accounts for third global incidence rate of human malignancies, whose development and progression occur significantly by Cyclooxygenase‐2 (COX‐2) as currently is considered to be a molecular target in tumor promotion during CRC progression. Specific COX-2 inhibitors can reportedly act an effective strategy to prevent and treat the human CRC. Materials and methods: The recently published articles in English were searched on PubMed database as well as findings presented at recent meetings were reviewed using keywords of Colorectal cancer, COX-2 inhibitors, clinical trials and treatment strategies. Results: The mortality rate of CRC patients has shown a reduction following the administration of selective COX-2 inhibitors before and after diagnosis of CRC. The incidence of certain cancers has been decreased by taking prophylactic Cox-2 inhibitors, including aspirin. The risk of adenoma and cancer was reduced in patients with familial CRC owing to the use of COX-2 (cyclooxygenase; prostaglandin-endoperoxide synthase-2 [PTGS2]) inhibitors during several randomized trials. Moreover, a reduction has been reported in polyp burden in individuals with FAP because of selective COX-2 inhibitors. The study of potent COX-2 inhibitors alone or in combination with other therapeutic agents is clinically ongoing to prevent polyp formation and to treat CRC among the general population. Conclusion: the results showed that CRC prophylaxis or therapy can be achieved through COX-2 inhibitors. However, there are needs for additional research to investigate the effectiveness of COX-2 inhibitors combined with other standard CRC treatment strategies before clinical measures.کلیدواژه ها
Colorectal cancer, COX-2 inhibitors, clinical trials, treatment strategiesمقالات مرتبط جدید
اطلاعات بیشتر در مورد COI
COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.
کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.